- Home
- AVTX vs YI Comparison
AVTX vs YI Comparison
Compare AVTX & YI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVTX
- YI
- Stock Information
- Founded
- AVTX 2011
- YI 2010
- Country
- AVTX United States
- YI China
- Employees
- AVTX N/A
- YI N/A
- Industry
- AVTX Biotechnology: Pharmaceutical Preparations
- YI Retail-Drug Stores and Proprietary Stores
- Sector
- AVTX Health Care
- YI Consumer Staples
- Exchange
- AVTX Nasdaq
- YI Nasdaq
- Market Cap
- AVTX 57.4M
- YI 56.5M
- IPO Year
- AVTX 2015
- YI N/A
- Fundamental
- Price
- AVTX $4.25
- YI $7.99
- Analyst Decision
- AVTX Strong Buy
- YI
- Analyst Count
- AVTX 6
- YI 0
- Target Price
- AVTX $34.20
- YI N/A
- AVG Volume (30 Days)
- AVTX 66.4K
- YI 9.8K
- Earning Date
- AVTX 05-20-2025
- YI 05-22-2025
- Dividend Yield
- AVTX N/A
- YI N/A
- EPS Growth
- AVTX N/A
- YI N/A
- EPS
- AVTX N/A
- YI N/A
- Revenue
- AVTX $441,000.00
- YI $1,973,017,082.00
- Revenue This Year
- AVTX N/A
- YI N/A
- Revenue Next Year
- AVTX N/A
- YI N/A
- P/E Ratio
- AVTX N/A
- YI N/A
- Revenue Growth
- AVTX N/A
- YI N/A
- 52 Week Low
- AVTX $4.15
- YI $0.41
- 52 Week High
- AVTX $16.00
- YI $11.35
- Technical
- Relative Strength Index (RSI)
- AVTX 31.02
- YI 49.55
- Support Level
- AVTX $4.80
- YI $7.48
- Resistance Level
- AVTX $5.26
- YI $8.40
- Average True Range (ATR)
- AVTX 0.45
- YI 0.42
- MACD
- AVTX 0.03
- YI -0.02
- Stochastic Oscillator
- AVTX 11.96
- YI 52.67
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.